Article Text

other Versions

PDF
Development and Validation of a Simple NAFLD Clinical Scoring System for Identifying Patients Without Advanced Disease
  1. Stephen Harrison MD (stephen.harrison{at}amedd.army.mil)
  1. Brooke Army Medical Center, United States
    1. Dana Oliver
    1. Saint Louis University, United States
      1. Hays L. Arnold MD
      1. Brooke Army Medical Center, United States
        1. Sudhanshu Gogia MD
        1. Saint Louis University, United States
          1. Brent A. Neuschwander-Tetri MD
          1. Saint Louis University, United States

            Abstract

            Background: Clinical predictors of advanced nonalcoholic liver disease (NAFLD) are needed to guide diagnostic evaluation and treatment.

            Methods: To better understand the demographics of NAFLD and risk factors for advanced disease, this study analyzed 827 NAFLD patients at two geographically separate tertiary medical centers.

            Results: The cohort was 51% female and had a median body mass index (BMI) of 33 kg/m2; 3% had a normal BMI. Common comorbidities included hypertension (60%) and diabetes (35%); insulin resistance was present in 91% and advanced fibrosis in 24% of patients. When comparing patients with no fibrosis or mild fibrosis to those with advanced fibrosis, BMI ≥ 28 kg/m2, age > 50, AST/ALT ratio (AAR) ≥ 0.8, QUICKI score <0.294 (equivalent to HOMA > 6.2) and the presence of DM were individually associated by univariate analysis with odds ratios (OR) of ≥2.4 for advanced fibrosis. Based on the results of a stepwise forced entry logistic regression analysis, three of these variables were combined in a weighted sum (BMI ≥ 28 = 1 point, AAR of ¡Ý0.8 = 2 points, DM = 1 point) to form an easily calculated composite score for predicting advanced fibrosis called the BARD score. A score of 2-4 was associated with an OR for advanced fibrosis of 17 (CI:9.2-31.9) and a negative predictive value of 9496%.

            Conclusions: Insulin resistance and its co-morbidities are often present in patients with NAFLD. An easily calculated score based on readily available clinical data can reliable reliably exclude the presence of advanced fibrosis in these patients, particularly among non-diabetics.

            Statistics from Altmetric.com

            Request permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

            Linked Articles